Biomaterial-based Implantable Cancer Vaccine Solutions

A: The main advantage is the creation of a "local immune niche." Scaffolds allow for much higher local concentrations of adjuvants and antigens with lower systemic toxicity. They actively recruit APCs to the vaccine site, ensuring efficient processing and presentation that systemic injections often miss due to dilution and off-target clearance.

A: Degradation is tuned during the synthesis phase by adjusting polymer molecular weight, cross-linking density, and the inclusion of biodegradable bonds (e.g., esters or enzymatically-cleavable peptides). We match the degradation rate to the required duration of the immune response, typically ranging from weeks to months in preclinical studies.

A: Yes. For non-resectable tumors, we focus on injectable hydrogels or in situ forming scaffolds. These are delivered via intratumoral injection as a liquid and solidify into a scaffold within the tumor, allowing for TME remodeling and immune activation without the need for major surgery.

A: We utilize various stabilization techniques, including protein-polymer conjugation, encapsulation within protective nanocarriers before scaffold integration, and the use of stabilizing excipients. Bioactivity is rigorously confirmed through in vitro release and functional assays before moving to in vivo studies.

A: Syngeneic murine models are most commonly used to ensure a fully functional immune system. We also utilize orthotopic models (e.g., surgical resection models for oral or breast cancer) to specifically evaluate postsurgical recurrence prevention, as well as humanized mouse models for testing human-specific antigens or checkpoint inhibitors.